Objective:

2

To investigate the anti-liver cancer effects and aspartic acid (Asp)-related action mechanism of

Euphorbia fischeriana

Steud. (LD).

Methods:

2

The mice model of liver cancer was established by injection of H22 cells. After 5 days

mice were randomly divided into model group

sorafenib group (20 mg/kg)

LD high-dose (LDH

1.36 g/kg) group

LD medium-dose (LDM

0.68 g/kg) group

and LD low-dose (LDL

0.34 g/kg) group

10 mice each group. Drugs were intragastrically administered to the mice once daily for 10 days

respectively. Body weight

tumor size and tumor weight were recorded. Hepatic index was calculated. Pathological changes of liver cancer tissues were evaluated by hematoxylin and eosin staining and TUNEL staining. Liquid chromatography-mass spectrometer was used to analyze different metabolites between the model and LDH groups.

Results:

2

After LD treatment

tumor weight

tumor size and hepatic index were reduced compared with the model group. Necrocytosis and karyorrhexis of tumor cells were found. Moreover

61 differential metabolites (18 up-regulated

43 down-regulated) were affirmed and 20 pathways of KE

GG (

P

<

0.05) were gotten. In addition

Bel-7402

HepG2 and H22 cell viabilities were significantly increased after adding Asp into the medium. And then

the cell proliferation effect induced by Asp was ameliorated by LD.

Conclusion:

2

The anti-liver cancer efficacy of LD extract was validated in H22 mice model

and inhibition of Asp level might be the underlying mechanism.